|3.||Acquired Immunodeficiency Syndrome (AIDS)
|4.||Extensively Drug-Resistant Tuberculosis
|1.||Isaakidis, Petros: 9 articles (12/2015 - 01/2013)|
|2.||Zumla, Alimuddin: 9 articles (05/2015 - 05/2010)|
|3.||Cho, Sang-Nae: 9 articles (03/2014 - 09/2007)|
|4.||Amaral, Leonard: 9 articles (12/2013 - 09/2005)|
|5.||Via, Laura E: 8 articles (12/2015 - 01/2010)|
|6.||Barry, Clifton E: 8 articles (03/2014 - 01/2010)|
|7.||Alffenaar, Jan-Willem C: 7 articles (10/2015 - 02/2010)|
|8.||van der Werf, Tjip S: 7 articles (10/2015 - 02/2010)|
|9.||Yew, Wing Wai: 7 articles (04/2015 - 10/2003)|
|10.||Viveiros, Miguel: 7 articles (01/2015 - 09/2005)|
|1.||Ofloxacin (Levofloxacin)FDA LinkGeneric
11/01/2006 - "In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. "
10/01/2015 - "Ofloxacin is widely used for the treatment of multidrug-resistant tuberculosis (MDR-TB). "
01/01/1999 - "Efficacy of low-dose ofloxacin in the treatment of multidrug-resistant tuberculosis in Indonesia."
03/29/2008 - "Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study."
04/01/2006 - "To investigate in vitro antituberculous activity of ofloxacin (OFLX) and levofloxacin (LVFX) against multidrug-resistant tuberculosis and to study the clinical outcomes. "
|2.||Isoniazid (Ftivazide)FDA LinkGeneric
05/01/2001 - "Therefore, isoniazid may be beneficial for the treatment of some cases of multidrug-resistant tuberculosis. "
09/01/2008 - "A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis."
02/01/2008 - "A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis."
04/01/2014 - "The rates of isoniazid (INH) and multidrug-resistant (MDR) tuberculosis (TB) among European children vary between 10.4% and 3.5%. "
09/25/2013 - "Response to comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis"."
|3.||Rifampin (Rifampicin)FDA LinkGeneric
10/01/2003 - "There has been a decrease in drug-resistant tuberculosis since 1980 for multiple reasons, including increased cure rates from the introduction of rifampin-based regimens, improved nutrition and living standards, and the treatment of drug-resistant cases in the private sector. "
02/01/2004 - "In addition, the method could be used in retrospective studies involving a wide range of PCR-based analyses, such as detection of rifampicin resistant gene in multidrug-resistant tuberculosis (MDR-TB) study."
11/01/2015 - "tuberculosis (MDR-TB), 21 (16.5%) were rifampicin mono-resistant and 37 (29.1%) were drug susceptible. "
11/01/2013 - "Based on drug susceptibility testing, 103 isolates were multidrug-resistant tuberculosis and 45 isolates were sensitive to isonicotinylhydrazine and rifampin. "
01/01/2013 - "Systematic review of the performance of rapid rifampicin resistance testing for drug-resistant tuberculosis."
|4.||Thioridazine (Mellaril)FDA LinkGeneric
03/01/2012 - "Thioridazine: an old neuroleptic effective against totally drug resistant tuberculosis."
05/01/2011 - "The advantages are that thioridazine is inexpensive, effective against drug resistant tuberculosis, well characterized and unlikely to induce drug resistance. "
01/15/2015 - "If these results are valid in humans, (-)-thioridazine may be a safer drug for treatment of multidrug-resistant tuberculosis and other microbes. "
06/01/2013 - "Recent clinical reports suggest that thioridazine may play a role in the treatment of drug-resistant tuberculosis. "
12/01/2012 - "The added effect of thioridazine in the treatment of drug-resistant tuberculosis."
|5.||linezolid (Zyvox)FDA Link
04/01/2009 - "Linezolid, the only marketed oxazolidinone, has been used off-label in combination regimens to treat multidrug-resistant tuberculosis, but its precise contribution to the efficacy of such combinations is unclear. "
12/01/2015 - "In this study, our objective was to explore the potential in vitro synergy between linezolid (LZD) and six other anti-TB drugs in Mycobacterium tuberculosis strains, especially multidrug-resistant tuberculosis (MDR-TB) strains. "
02/01/2010 - "This study showed that linezolid AUC0-12h in patients with multidrug-resistant tuberculosis could be predicted accurately by a minimal sampling strategy and could be used to individualize the dose."
12/01/2015 - "Linezolid in drug-resistant tuberculosis: haste makes waste."
12/01/2015 - "Linezolid in drug-resistant tuberculosis: haste makes waste."
11/04/2006 - "High mortality rates in co-infected patients have improved with antiretroviral therapy, but drug-resistant tuberculosis has emerged as a major cause of death. "
01/01/2015 - "Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe Tropical Disease Hospital Johannesburg, South Africa."
03/21/2014 - "Infection control in households of drug-resistant tuberculosis patients co-infected with HIV in Mumbai, India."
01/01/2014 - "Fifty seven (57) patients with drug-resistant tuberculosis were identified, 31 (53%) of whom were HIV co-infected. "
12/01/2013 - "Viral load for HIV treatment failure management: a report of eight drug-resistant tuberculosis cases co-infected with HIV requiring second-line antiretroviral treatment in Mumbai, India."
02/01/2013 - "Previous studies have demonstrated that cells from both multi-drug-resistant tuberculosis (MDR-TB) and non-tuberculous mycobacteria (NTM) patients respond poorly to mycobacterial antigens in vitro. "
09/01/2008 - "The aim of this study was to evaluate CD4+IFN-gamma+, CD4+IL-10+, CD8(+)IFN-gamma+ and CD8+IL-10+ cell populations by flow cytometry in non-resistant TB and multi-drug resistant tuberculosis (MDR-TB) patients from mid-central Brazil after stimulation with MPT-51, GlcB and ESAT-6 recombinant antigens from M. "
08/01/2007 - "Evaluation of T cell immune responses in multi-drug-resistant tuberculosis (MDR-TB) patients to Mycobacterium tuberculosis total lipid antigens."
08/01/2007 - "tuberculosis total lipid antigens in T lymphocytes from 25 patients with multi-drug-resistant tuberculosis (MDR-TB). "
06/01/2003 - "The production of tumour necrosis factor-alpha is decreased in peripheral blood mononuclear cells from multidrug-resistant tuberculosis patients following stimulation with the 30-kDa antigen of Mycobacterium tuberculosis."
|8.||butyl 3-(1H-tetrazol-5-yl)oxanilate (MTB)IBA
10/01/2011 - "Improved rapid molecular diagnosis of multidrug-resistant tuberculosis using a new reverse hybridization assay, REBA MTB-MDR."
01/01/2015 - "The current study restricts analysis to patients with multidrug resistant tuberculosis who were diagnosed using rapid diagnostic methods (Xpert MTB/RIF or the line probe assay). "
08/01/2011 - "The aim of this study was to genotypically characterize the MTB isolates from patients with pulmonary drug-resistant tuberculosis (DR-TB) in Greece, and to determine whether there is any association between the prevalent genotypes and drug resistance. "
12/01/2015 - "Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia."
12/01/2015 - "Pyridone 1 was identified from a high-throughput cell-based phenotypic screen against Mycobacterium tuberculosis (Mtb) including multi-drug resistant tuberculosis (MDR-TB) as a novel anti-TB agent and subsequently optimized series using cell-based Mtb assay. "
|9.||moxifloxacin (Avelox)FDA Link
02/15/2015 - "In a prospective pharmacokinetic and safety study, children 7-15 years of age routinely receiving moxifloxacin 10 mg/kg daily as part of multidrug treatment for MDR tuberculosis in Cape Town, South Africa, for at least 2 weeks, underwent intensive pharmacokinetic sampling (predose and 1, 2, 4, 8, and either 6 or 11 hours) and were followed for safety. "
02/15/2015 - "Moxifloxacin was well tolerated in children treated for MDR tuberculosis."
02/15/2015 - "Children 7-15 years of age receiving moxifloxacin 10 mg/kg/day as part of MDR tuberculosis treatment have low serum concentrations compared with adults receiving 400 mg moxifloxacin daily. "
02/15/2015 - "Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis."
10/01/2012 - "Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?"
|10.||Ethionamide (Trecator-SC)FDA Link
01/01/2011 - "Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis."
12/01/2015 - "Ethionamide (ETH) is an antibiotic used for the treatment of multidrug-resistant (MDR) tuberculosis (TB) (MDR-TB), and its use may be limited with the emergence of resistance in the Mycobacterium tuberculosis population. "
12/01/2015 - "Ethionamide, 2-ethylpyridine-4-carbothioamide, is a second-line antituberculosis drug used for the treatment of multidrug-resistant tuberculosis. "
05/01/2012 - "It is, therefore, necessary to revisit the susceptibility testing method for ethionamide for effective clinical management of patients with drug resistant tuberculosis."
10/01/2006 - "Ethionamide is one of the most widely used drugs for the treatment of multidrug-resistant tuberculosis (MDR-TB). "
|1.||Drug Therapy (Chemotherapy)
06/01/2008 - "To investigate the therapeutic efficacy of short course chemotherapy (SCC) on drug resistant tuberculosis (DR-TB) cases and related influencing socioeconomic factors. "
10/05/1995 - "In this report from New York City, HIV-negative patients with multidrug-resistant tuberculosis, contrary to previous reports, responded well to appropriate chemotherapy, both clinically and microbiologically."
01/01/2007 - "Clinical studies indicated that 1-6-month concurrent use of chemotherapy and pO3 in patients with drug-resistant tuberculosis eliminated drug resistance of isolated MBT to one of the drugs (I, R, K) in 97.3%, MBT became at once susceptible to I, R, and K in 47.2%. "
10/15/1996 - "The emergence of multidrug-resistant tuberculosis has renewed interest in the study of drug resistance in mycobacteria with the objective of improved chemotherapy. "
01/01/2012 - "Efficacy of remaxol in complex chemotherapy of generalized drug resistant tuberculosis was studied on mice. "
06/01/2004 - "However, the high proportion of MDR tuberculosis among patients with treatment after failure poses a challenge to the efficacy of the retreatment regimen."
10/01/2015 - "Drug resistant tuberculosis prevention and control in Ningxia should be focused on newly diagnosed single drug-resistant cases, retreatment multiple-drug resistant cases, and drug resistant cases in minority areas."
10/01/2015 - "The prevalence of multidrug-resistant tuberculosis (TB) among new and retreatment cases in 2011 in Ethiopia was 2.7% and 17.9%, respectively. "
05/01/2013 - "To examine direct and indirect costs incurred by new, retreatment, and multidrug-resistant (MDR) tuberculosis (TB) patients in the Dominican Republic before and during diagnosis, and during treatment, to generate an evidence base and formulate recommendations. "
01/01/2013 - "retreatment cases) multidrug-resistant tuberculosis (MDR-TB) from the eastern region of Libya in 1971 were 16.6 and 33.3% and in 1976 were 8.6 and 14.7%, in western regions in 1984-1986 were 11 and 21.5% and in the whole country in 2011 were estimated at 3.4 and 29%, respectively. "
|3.||Highly Active Antiretroviral Therapy (HAART)
03/01/2013 - "The impact of the human immunodeficiency virus (HIV) on multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in sub-Saharan Africa, where extensive rollout of highly active antiretroviral therapy (HAART) has occurred, remains unclear. "
01/01/2012 - "HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era."
06/01/2010 - "The proportion with multidrug-resistant tuberculosis decreased (from 16% to 4%; P < .001 for trend), especially from pre-HAART to early HAART (aOR, 0.31; 95% CI, 0.25-0.40). "
01/01/2001 - "[Improved prognosis in HIV/AIDS related multi-drug resistant tuberculosis patients treated with highly active antiretroviral therapy]."
05/15/2010 - "Transmission of drug-susceptible and drug-resistant tuberculosis and the critical importance of airborne infection control in the era of HIV infection and highly active antiretroviral therapy rollouts."
05/01/2015 - "Paediatric chemoprophylaxis for child contacts of drug-resistant tuberculosis cases: Are current guidelines effective in preventing disease?"
04/01/2011 - "Active research is required to answer the unresolved issues of finding optimal diagnostic tools, treatment regimens and duration and chemoprophylaxis in pediatric drug resistant tuberculosis."
12/01/2007 - "There is little published information on optimal chemoprophylaxis for children with multidrug-resistant tuberculosis (MDR-TB) contacts. "
12/01/2007 - "Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases."
10/01/2005 - "To evaluate the current situation of contacts examination and chemoprophylaxis for those who were exposed to multi-drug resistant tuberculosis (MDR-TB) in Japan. "
06/01/2014 - "Novel diagnostics and therapeutics for drug-resistant tuberculosis."
01/01/2013 - ": The emergence of multidrug resistant tuberculosis (MDRTB) highlights the urgent need to understand the mechanisms of resistance to the drugs and to develop a new arena of therapeutics to treat the disease. "
02/01/2013 - "Current anti-tuberculosis therapeutics are not sufficiently effective against drug-resistant tuberculosis (DR-TB), and there is a need for new drugs and therapeutic approaches. "
01/01/2012 - "The emergence of Multi-drug resistant tuberculosis in pandemic proportions throughout the world and the paucity of novel therapeutics for tuberculosis have re-iterated the need to accelerate the discovery of novel molecules with anti-tubercular activity. "